Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2018 5
2019 3
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Expression profile of HLA-B*38:55Q allele.
Fusco C, Cervelli C, Dal Mas A, Canossi A, Azzarone R, Valdez O, Auriemma L, Madalese D, Maisto G, Toriello M, Penta de Vera d'Aragona R, Scimitarra M, Scarnecchia MA, Battistoni C, Fracassi D, Papola F. Fusco C, et al. Among authors: dal mas a. HLA. 2020 May;95(5):449-456. doi: 10.1111/tan.13790. Epub 2020 Jan 6. HLA. 2020. PMID: 31891446
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.
Irelli A, Parisi A, D'Orazio C, Sidoni T, Rotondaro S, Patruno L, Pavese F, Bafile A, Resta V, Pizzorno L, Ciuffetelli V, Dal Mas A, Calvisi G, Di Sibio A, Marzullo A, Zelli V, Compagnoni C, Tessitore A, Alesse E, Ficorella C, Cortellini A, Cannita K. Irelli A, et al. Among authors: dal mas a. Cancers (Basel). 2022 Jun 18;14(12):3003. doi: 10.3390/cancers14123003. Cancers (Basel). 2022. PMID: 35740668 Free PMC article.
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.
Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Cortellini A, et al. Among authors: dal mas a. Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019. Onco Targets Ther. 2019. PMID: 30988620 Free PMC article.
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice.
Bruera G, Pepe F, Malapelle U, Di Staso M, Dal Mas A, Di Giacomo D, Scerbo G, Santilli M, Ciacco E, Simmaco M, Troncone G, Coco C, Giuliante F, Ricevuto E. Bruera G, et al. Among authors: dal mas a. Ann Transl Med. 2021 Jun;9(12):1027. doi: 10.21037/atm-20-6636. Ann Transl Med. 2021. PMID: 34277827 Free PMC article.
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C. Cocciolone V, et al. Among authors: dal mas a. Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270. eCollection 2018 Jun 8. Oncotarget. 2018. PMID: 29937992 Free PMC article.
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.
Bruera G, Massacese S, Galvano A, Mas AD, Guadagni S, Calvisi G, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Bruera G, et al. Among authors: mas ad. Oncotarget. 2018 Apr 17;9(29):20339-20350. doi: 10.18632/oncotarget.24861. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755655 Free PMC article.
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, Calvisi G, Troncone G, Simmaco M, Ricevuto E. Bruera G, et al. Among authors: dal mas a. Ther Adv Med Oncol. 2019 May 10;11:1758835919846421. doi: 10.1177/1758835919846421. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31205502 Free PMC article.
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.
Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E. Bruera G, et al. Among authors: mas ad. Oncotarget. 2018 May 29;9(41):26279-26290. doi: 10.18632/oncotarget.25180. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899858 Free PMC article.
14 results